A New Anti-oestrogenic Agent in Late Breast Cancer: An Early Clinical Appraisal of ICI46474 (original) (raw)

Abstract

An introductory clinical trial of the anti-oestrogenic agent IC146474 in late or recurrent carcinoma of the breast is described.

Forty-six patients have been treated, of whom 10 have shown a good response. This is of the same order as that seen with oestrogens and androgens.

The particular advantage of this drug is the low incidence of troublesome side effects.

Access through your institution

Buy or subscribe

This is a preview of subscription content, access via your institution

Access options

Access through your institution

Subscribe to this journal

Receive 24 print issues and online access

$259.00 per year

only $10.79 per issue

Learn more

Buy this article

USD 39.95

Prices may be subject to local taxes which are calculated during checkout

Additional access options:

Similar content being viewed by others

Precision therapeutics and emerging strategies for HR-positive metastatic breast cancer

Article 23 August 2024

An emerging generation of endocrine therapies in breast cancer: a clinical perspective

Article Open access 05 April 2023

Results of the phase IIa RADICAL trial of the FGFR inhibitor AZD4547 in endocrine resistant breast cancer

Article Open access 10 June 2022

Authors

  1. M P Cole
    View author publications
    Search author on:PubMed Google Scholar
  2. C T A Jones
    View author publications
    Search author on:PubMed Google Scholar
  3. I D H Todd
    View author publications
    Search author on:PubMed Google Scholar

Rights and permissions

Reprints and permissions

About this article

Cite this article

Cole, M., Jones, C. & Todd, I. A New Anti-oestrogenic Agent in Late Breast Cancer: An Early Clinical Appraisal of ICI46474.Br J Cancer 25, 270–275 (1971). https://doi.org/10.1038/bjc.1971.33

Download citation

This article is cited by